Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atexakin alfa (Alixer Nexgen Therapeutics)
- Development stage
- Unknown
- Lead developer
- Alixer Nexgen Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ALK203 (atexakin alfa) is a recombinant human interleukin-6 (rhIL-6) protein being developed by Alixer Nexgen Therapeutics for the treatment of diabetic peripheral neuropathy (DPN). While interleukin-6 is commonly recognized as a pro-inflammatory cytokine, ALK203 utilizes its neurotrophic and regenerative properties to address nerve damage. The drug acts as an agonist of the IL-6 receptor complex, activating signaling pathways that promote nerve growth, enhance vascular repair, and stimulate axonal regeneration. By targeting these pathways, ALK203 aims to restore peripheral nerve function and alleviate the symptoms of neuropathy in diabetic patients. It is currently in Phase 2 clinical development.
- Other names
- recombinant human interleukin-6rhIL-6rhIL6rhIL 6
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)IL6ST (Interleukin-6 receptor subunit beta)
Beyond the preview
Go deeper on atexakin alfa (Alixer Nexgen Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atexakin alfa (Alixer Nexgen Therapeutics).